HENDERSON, Nev., Dec. 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, issues a Business Review of 2025. Review of the Year by Cameron Reynolds, Group Chief Executive Officer As 2025 draws to a close, I would like to take this opportunity to look back on the year's key milestones and look to the opportunities ahead. Before diving into the detail, I would like to take a moment to reflect on our founding mission. We set out over fifteen year ...